• PDB3 COMPARING EFFICIENCY OF INSULIN GLARGINE VS. NPH INSULIN IN PATIENTS WITHTYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PHP21 IMPACT OF DISCONTINUITY IN HEALTH INSURANCE ON RESOURCE UTILIZATION

    Nov 1, 2007, 00:00

  • PAA21 DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL

    Nov 1, 2007, 00:00

  • PCV1 AN OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF ROSUVASTATIN IN PATIENTS WITH DIABETES IN GENERAL PRACTICE ACROSS THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PRS8 S-MEDDIAL PROJECT OF COOPERATION WITH PEDIATRICIANS ON PROVIDING INDIVIDUAL FEEDBACK ON ANTIBIOTICS PRESCRIPTION IN ORDERTO IMPROVE PRESCRIPTION HABITS AND TO RATIONALIZE DRUG SPENDING

    Nov 1, 2007, 00:00

  • PND1 BUDGETARY ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA)

    Nov 1, 2007, 00:00

  • PSK8 ASSESSMENT OF INVOLVED BODY SURFACE AREA (BSA) IN PSORIASIS PATIENTS. VALIDATION OF SOFTWARE ASSISTED DIAGNOSIS BSA FOR THE MANAGEMENT OF PSORIASIS

    Nov 1, 2007, 00:00

  • MD4 COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING COMBINED WITH ALENDRONATE THERAPY FOR THOSE WHO HAVE OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • PAA1 SUB-ACUTE LACK OF ASTHMA CONTROL AND SUBSEQUENT ACUTE ASTHMA EXACERBATIONS- EVIDENCE FROM MANAGED CARE DATA

    Nov 1, 2007, 00:00

  • PSM1 COST-EFFECTIVENESS ANALYSIS OF CHAMPIX® (VARENICLINE) IN SMOKING CESSATION TREATMENT IN SPAIN

    Nov 1, 2007, 00:00

  • PND33 THE RELATIONSHIP BETWEEN THE MEDICATION POSSESSION RATIO AND PATIENT OUTCOMES- EVIDENCE FROM THE USE OF GLATIRAMER ACETATE

    Nov 1, 2007, 00:00

  • PIN27 THE COST-EFFECTIVENESS OF UNIVERSAL INFLUENZA VACCINATION FOR 50-64 YEAR-OLDS IN AUSTRALIA

    Nov 1, 2007, 00:00

  • PSM2 A COST—EFFECTIVENESS ANALYSIS OF A COMMUNITY PHARMACIST BASED SMOKING CESSATION PROGRAM IN THAILAND

    Nov 1, 2007, 00:00

  • PCV47 COST-EFFECTIVENESS OF ENDOVASCULAR REPAIR (EVAR) COMPARED WITH OPEN SURGERY REPAIR (OSR) FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSM (AAA) IN ITALY

    Nov 1, 2007, 00:00

  • PDB60 ASSOCIATION OF INADEQUATE METABOLIC CONTROL AND CO-MORBIDITIES AND HEALTH RESOURCE UTILIZATION IN PATIENTS WITH DIABETES MELLITUS IN A SPANISH POPULATION

    Nov 1, 2007, 00:00

  • POB3 A PROBABILISTIC BAYESIAN MARKOV MODEL IN WINBUGS FOR THE ECONOMIC EVALUATION OF THE TREATMENT WITH ORLISTAT OF ITALIAN OBESE PATIENTS

    Nov 1, 2007, 00:00

  • HP4 PROMOTING A DRUG'S HEALTH ECONOMIC ADVANTAGES IN MEDICAL JOURNAL ADVERTISING IN THE U.S.- A REVIEW OF 3,500 ADS FROM 1990–2006

    Nov 1, 2007, 00:00

  • PCV84 WHAT FACTORS AFFECT COMPLIANCE OF HYPERTENSIVE PATIENTS WITH THEIRTREATMENT? A QUALITATIVE STUDY

    Nov 1, 2007, 00:00

  • PHM20 VALUE OF TRANSFUSION-FREE LIVING IN MDS- RESULTS OF HEALTH UTILITY INTERVIEWS WITH MDS PATIENTS

    Nov 1, 2007, 00:00

  • PMH11 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA- 12 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA

    Nov 1, 2007, 00:00

  • PHP32 OBTAINING VALUE FOR MONEY FROM PHARMACEUTICALS- REFERENCE PRICING OR HEALTH TECHNOLOGY ASSESSMENT?

    Nov 1, 2007, 00:00

  • PMH5 THE COMPARATIVE EFFICACY OF SECOND-GENERATION ANTIDEPRESSANTS FORTHE ACUTE-PHASE TREATMENT OF MAJOR DEPRESSIVE DISORDER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2007, 00:00

  • CV1 POST-AMI DRUGTHERAPY PERSISTENCE AND RISK OF REINFARCTION IN A MEDICAID POPULATION

    Nov 1, 2007, 00:00

  • PMS2 PATIENT-REPORTED-OUTCOMES (PRO) AS A DRIVEN OF DIRECT HEALTH COSTS IN SUBJECTS WITH FIBROMYALGIA A LONGITUDINAL RETROSPECTIVE PRIMARY CARE SETTINGS (PCS) CLAIM DATABASE ANALYSIS

    Nov 1, 2007, 00:00

  • PDB65 THE PROSIT DISEASE MODELLING COMMUNITY—OPEN SOURCE DEVELOPMENT OF DECISION ANALYTIC DISEASE MODELS FOR TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PG128 IMPACT OF CERTOLIZUMAB PEGOL ON QUALITY-ADJUSTED LIFE-YEARS IN TWO INDUCTION AND MAINTENANCE TRIALS IN PATIENTS WITH ACTIVE CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PIN31 TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS IN BELGIUM

    Nov 1, 2007, 00:00

  • SU3 NINEYEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING IN CONTEXT OF SURVIVAL AND COMPLICATIONS

    Nov 1, 2007, 00:00

  • PCV33 RESOURCE USE AND TREATMENT COSTS FORACUTE DECOMPENSATED HEART FAILURE- ECONOMIC ANALYSIS OF THE SURVIVE TRIAL

    Nov 1, 2007, 00:00

  • PND35 MEASURING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE- A SYSTEMATIC REVIEW

    Nov 1, 2007, 00:00

  • PCV2 EFFECTIVENESS OF MULTIPLE-MECHANISM ANTIHYPERTENSIVE MEDICATION- VALSARTAN-AMLODIPINE-HCTZ TRIPLE-THERAPY IN PRIMARY CARE

    Nov 1, 2007, 00:00

  • PDB34 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF A MODERN INSULIN IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES IN THE GERMAN SETTING; DATA FROMTHE PREDICTIVE STUDY

    Nov 1, 2007, 00:00

  • PCV15 IMPACT OF CHANGES IN REIMBURSEMENT SYSTEM ON THE BUDGET FROM THE PAYER'S AND PATIENT'S PERSPECTIVE

    Nov 1, 2007, 00:00

  • PMH56 A REVIEW OF INSTRUMENTS USED TO ASSESS THE IMPACT OF ALCOHOLISM ON QUALITY OF LIFE

    Nov 1, 2007, 00:00

  • PAR21 IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PHM9 COST OF ILLNESS OF DIFFUSE LARGE B-CELL LYMPHOMA IN RUSSIA

    Nov 1, 2007, 00:00

  • EC4 COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING

    Nov 1, 2007, 00:00

  • PAA12 EXTENT OF UNCONTROLLED DISEASE AND ASSOCIATED MEDICAL COSTS IN SEVERE ASTHMA IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PIH4 DRUG COSTS AT THE END OF LIFE

    Nov 1, 2007, 00:00

  • PMC24 THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE (SIAQ®)- DEVELOPMENT AND CONTENT VALIDATION

    Nov 1, 2007, 00:00

  • PG11 DETERMINATION OF MINIMAL IMPORTANT DIFFERENCES (MIDS) AND INTERPRETATION OF SF-36 SCORES IN PATIENTS SUFFERING FROM MODERATE-TO-SEVERE CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PUK19 TREATMENT OUTCOMES AND MEDICAL CARE OF PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) RECEIVING BOTULINUM TOXIN A (BOTOX®) THERAPY

    Nov 1, 2007, 00:00

  • PMH50 A BELGIAN PILOT PROJECT TESTING THE FEASIBILITY AND ACCEPTABILITY OF SHORT MESSAGE SERVICE (SMS)TEXT MESSAGING TO PATIENTS TREATED WITH QUETIAPINE

    Nov 1, 2007, 00:00

  • PCV83 ADHERENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT- EVIDENCE FROM PRIMARY CARE PRACTICE IN ITALY

    Nov 1, 2007, 00:00

  • PHP20 THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE

    Nov 1, 2007, 00:00

  • PAA6 COST EFFECTIVENESS OF BREATH-OPERATED INHALERS IN UNITED KINGDOM PRIMARY CARE

    Nov 1, 2007, 00:00

  • Patient-Reported Outcomes- Instrument Development and Selection Issues

    Nov 1, 2007, 00:00

  • PIH6 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH TRAUMATIC INJURY AMONG PEDIATRICS IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PCN65 RESULTS FROM MABEL- QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC)

    Nov 1, 2007, 00:00

  • PEN1 TIME-AND-MOTION EVALUATION OF DIFFERENT GROWTH HORMONE FORMULATIONS

    Nov 1, 2007, 00:00

  • PIN25 A COST-EFFECTIVENESS STUDY OF A UNIVERSAL VACCINATION PROGRAM WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7) IN SWEDEN

    Nov 1, 2007, 00:00

  • PHP19 IMMUNIZATION PROGRAM IN PARAGUAY- SOCIAL AND BEHAVIORAL DETERMINANTS AND ORGANIZATIONAL IMPACT

    Nov 1, 2007, 00:00

  • PIN39 ECONOMIC EVALUATION OF A UNIVERSAL CHILDHOOD PNEUMOCOCCAL CONJUGATE VACCINATION STRATEGY IN IRELAND

    Nov 1, 2007, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2007, 00:00

  • PIH16 INTERNET SURVEY- A NEW AND VALID TOOL TO ESTIMATE THE BURDEN OF OTITIS IN CHILDREN 5 YEARS OLD

    Nov 1, 2007, 00:00

  • DB1 IMPACT OF ROSIGLITAZONETHERAPY ONTHE LIPID PROFILE AND LIPID-LOWERINGTREATMENT IN TYPE 2 DIABETES PATIENTS

    Nov 1, 2007, 00:00

  • PIN47 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF THE VACCINEES' PERCEPTION OF INJECTION (VAPI) QUESTIONNAIRE TO ASSESS SUBJECTS' ACCEPTANCE OF INFLUENZA VACCINATION

    Nov 1, 2007, 00:00

  • PDB75 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ) FOR USE IN EASTERN EUROPE

    Nov 1, 2007, 00:00

  • PSM6 REAL WORLD USAGE PATTERNS OF OVER-THE-COUNTER NICOTINE PATCHES

    Nov 1, 2007, 00:00

  • PCV49 BUDGET IMPACT AND MEDICAL RESOURCES USED TO CONTROL BLEEDS IN PATIENTS HOSPITALIZED DUE TO ACUTE CORONARY SYNDROME (ACS)

    Nov 1, 2007, 00:00

  • PDB1 GLYCEMIC CONTROL GOAL ATTAINMENT AMONGTYPE 2 DIABETIC PATIENTSWHO INITIATED ORAL COMBINATION THERAPY IN HUNGARY

    Nov 1, 2007, 00:00

  • PMH16 ASSOCIATION BETWEEN ATYPICAL ANTIPSYCHOTIC USE AND TREATMENT-EMERGENT DIABETES, HYPERLIPIDEMIA, AND OBESITY

    Nov 1, 2007, 00:00

  • PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL

    Nov 1, 2007, 00:00

  • PCV22 COST EFFECTIVENESS ANALYSIS OF BOSENTAN FORTHE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN SOUTH KOREA

    Nov 1, 2007, 00:00

  • PCV27 ECONOMIC EVALUATION OF NEBIVOLOL COMPARED WITH PLACEBO IN ELDERLY PATIENTS WITH HEART FAILURE -A MODEL BASED ANALYSIS ALONGSIDE THE SENIORS TRIAL

    Nov 1, 2007, 00:00

  • PND36 FIT OF THE MIGRAINE PREVENTION ASSESSMENT CLINICAL TOOL (M-PACT)WITH QUALITATIVE DEVELOPMENT GUIDELINES FOR PATIENT REPORTED OUTCOMES

    Nov 1, 2007, 00:00

  • PDB71 PILOT STUDY OF CLINICIAN ATTITUDES TO PUMP THERAPY- INTERNATIONAL DIFFERENCES AND THE NEED FORA GREATER UNDERSTANDING OF THE PATIENT PERSPECTIVE

    Nov 1, 2007, 00:00

  • PG19 PHARMACOECONOMIC ANALYSIS OF GERD TREATMENT AFTER OMEPRAZOLE FAILURE IN SPAIN

    Nov 1, 2007, 00:00

  • PCV66 COMPARING QUALITY OF CARE- IS IT MEANINGFUL?

    Nov 1, 2007, 00:00

  • PRS5 REDUCTION IN TOTAL TREATMENT COSTS THROUGH IMPROVED PHARMACEUTICAL TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES

    Nov 1, 2007, 00:00

  • PDB25 COST-EFFECTIVENESS OF DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A BELGIUM SETTING, A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OFTHREE CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PIH13 FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING FOR BREAST CANCER

    Nov 1, 2007, 00:00

  • PCN12 COST-EFFECTIVENESS OFTARGETED ONCOLOGY THERAPIES-A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2007, 00:00

  • PMH26 USING THE NET-BENEFIT REGRESSION APPROACH TO COMPARE THE COST-EFFECTIVENESS OF HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • PIN5 COST-EFFECTIVENESS OFTIGECYLINE IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN GERMANY

    Nov 1, 2007, 00:00

  • PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN

    Nov 1, 2007, 00:00

  • PIN9 A COST-EFFECTIVENESS ANALYSIS OF A YEARLY FIBROSCAN® LIVER FIBROSIS ASSESSMENT COMPARED WITH A PERIODIC LIVER BIOPSY IN HEPATITIS C VIRUS (HCV) INFECTED INDIVIDUALS IN A FRENCH SETTING

    Nov 1, 2007, 00:00

  • PND12 MODELING THE CLINICAL AND ECONOMIC CONSEQUENCES OF TREATING RELAPSING FORM OF MULTIPLE SCLEROSIS WITH SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON-BETA-IA

    Nov 1, 2007, 00:00

  • PMC23 VALIDITY OF THE SPANISH SF-6D TARIFFS AND EQ-5D COMPARING THE UTILITY VALUES OBTAINED IN FOUR DIFFERENT GROUPS OF PATIENTS

    Nov 1, 2007, 00:00

  • PPN4 HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN

    Nov 1, 2007, 00:00

  • PRS12 MAPPING THE EQ-5D FROM THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN A CLINICAL TRIAL OF COPD TREATMENTS—RESULTS FROM THE OPTIMAL TRIAL

    Nov 1, 2007, 00:00

  • PEY4 COST-EFFECTIVENESS ANALYSIS OF FIXED COMBINATION THERAPIES GANFORT, DUOTRAV AND XALACOM IN EUROPEAN COUNTRIES

    Nov 1, 2007, 00:00

  • PG112 THE DUEC (DIGITAL ULCERS ECONOMIC COST) STUDY- ECONOMIC BURDEN OF DIGITAL ULCERS IN ITALIAN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS

    Nov 1, 2007, 00:00

  • PMH13 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- 18 MONTH INTERIM RESULTS FROM BELGIAN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA TREATMENT A ...

    Nov 1, 2007, 00:00

  • ED1 COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN A GERMAN SETTING. A MODELING EVALUATION BASED UPON RESULTS FROM A META-ANALYSIS

    Nov 1, 2007, 00:00

  • PMH35 SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND- A COST ANALYSIS

    Nov 1, 2007, 00:00

  • PHP1 ECONOMIC ANALYSIS OF THE BAVARIAN BLOOD AND PLASMA MARKET- LESSONS FOR THE FUTURE

    Nov 1, 2007, 00:00

  • PIN38 AFFORDABILITYOFANTIMALARIAL DRUGS IN BENIN CITY, NIGERIA

    Nov 1, 2007, 00:00

  • POB2 REDUCING GLOBAL CARDIOMETABOLIC RISK IN OVERWEIGHT OR OBESE INDIVIDUALS WITH DYSLIPIDEMIA- PROJECTED BENEFITS OF RIMONABANT IN A REAL WORLD POPULATION

    Nov 1, 2007, 00:00

  • PND11 COMPARATIVE ANALYSIS OF MULTIPLE SCLEROSIS COST-EFFECTIVENESS MODELS- FOCUS ON THE UNITED STATES MANAGED CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PHP13 THE COST OF WASTED MEDICINES IN PORTUGAL

    Nov 1, 2007, 00:00

  • CN3 EFFECTIVENESS OF EPOETIN ALPHA VERSUS DARBEPOETIN IN CHEMOTHERAPY-INDUCED ANAEMIA INTHE GERMAN SETTING

    Nov 1, 2007, 00:00

  • PDB46 COST-UTILITY OF INSULIN DETEMIR VERSUS NPH FOR TYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A FRENCH SETTING, A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PND20 COST-UTILITY ANALYSIS EVALUATING THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY

    Nov 1, 2007, 00:00

  • PCV92 ATTITUDES AND BELIEFS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK, ABOUT HYPERCHOLESTEROLEMIA AND ITS TREATMENT IN SPAIN. THE PRACTICE STUDY

    Nov 1, 2007, 00:00

  • PHP6 NETWORKING TOWARDS FUNCTIONAL POLICY-TOOLS- CAN CONDITIONAL REIMBURSEMENT OF DRUGS LEAD TO EFFICIENT AND EFFECTIVE DRUG USE?

    Nov 1, 2007, 00:00

  • PDB73 PSYCHOMETRIC EVALUATION OF THE DIABETES SYMPTOM CHECKLIST- REVISED (DSC-R)- FACE, CONTENT AND CONSTRUCT VALIDITY

    Nov 1, 2007, 00:00

  • PDB18 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE-AN ECONOMIC EVALUATION PROJECTING RESULTS FROM A CLINICAL STUDY INTOTHE FUTURE USING AVALID AND RELIABLE ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA

    Nov 1, 2007, 00:00

  • PIN3 AWORKSITE INFLUENZA VACCINATION PROGRAM IN RUSSIAA COST-BENEFIT ANALYSIS

    Nov 1, 2007, 00:00

  • PMH22 A PHARMACOECONOMIC ANALYSIS OF COMPLIANCE GAINS ON ANTIPSYCHOTIC MEDICATIONS

    Nov 1, 2007, 00:00

  • PMH39 ESTIMATION OF THE RESOURCE UTILIZATION AND METABOLIC CONTROL ASSOCIATED WITH DEPRESSIVE SYNDROME IN PATIENTS WITH STROKE

    Nov 1, 2007, 00:00

  • PCV77 RESPONSE-SHIFT IN HEART DISEASE- COMPARING INDIVIDUALIZED VS. DISEASE-SPECIFIC HRQL INSTRUMENTS

    Nov 1, 2007, 00:00

  • PIN35 MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B-A COST-EFFECTIVENESS ANALYSIS OF ENTECAVIR IN SPAIN

    Nov 1, 2007, 00:00

  • PMH46 THE SENSITIVITYTO CHANGE OF THE HAMILTON (HAMD) AND THE MONTGOMERY-ASBERG (MADRS) SCALES AS OUTCOME MEASURES IN ANTIDEPRESSANT TRIALS

    Nov 1, 2007, 00:00

  • PCN29 COST-EFFECTIVENESS OF MAINTENANCE RITUXIMAB TREATMENT AFTER SECOND LINE THERAPY IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA IN SWEDEN

    Nov 1, 2007, 00:00

  • PRS9 ECONOMIC EFFECTS AND SUSTAINABILITY OF A STRUCTURED CARE PROGRAMME FOR COPD PATIENTS

    Nov 1, 2007, 00:00

  • PCN3 ECONOMIC IMPACT OF SECOND- ANDTHIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER-A FRENCH OBSERVATIONAL STUDY

    Nov 1, 2007, 00:00

  • PMH29 SWITCHING FROM BRANDED TO GENERIC RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA- AN ESTIMATION OF POTENTIAL ECONOMIC CONSEQUENCES IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PDB68 ISA MEASUREMENT-GUIDED INTERVENTION PROGRAM TO LENGTHEN PERSISTENCE WITH METFORMIN MONOTHERAPY COST EFFECTIVE IN TYPE 2 DIABETES?

    Nov 1, 2007, 00:00

  • POS2 CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES

    Nov 1, 2007, 00:00

  • PCV69 SIMPLE SENSITIVITY ANALYSIS TO ASSESS THE IMPACT OF ROUNDING OF BLOOD PRESSURE MEASUREMENTS ON ESTIMATES OF CONTROL RATES

    Nov 1, 2007, 00:00

  • PMH38 INFLUENCE OF BEHAVIOURAL SYMPTOMS ON RESOURCES USE IN DEMENTIA

    Nov 1, 2007, 00:00

  • PCN62 USE OF A 5-LEVEL EQ-5D IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

    Nov 1, 2007, 00:00

  • PHP18 HEALTH CARE DECISION-MAKERS'ATTITUDE ON HEALTH ECONOMICS RESEARCH

    Nov 1, 2007, 00:00

  • PAR23 COST-UTILITY OF ABATACEPT, A NEW BIOLOGIC TREATMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO FAILED ANTI-TNF THERAPY

    Nov 1, 2007, 00:00

  • PDB6 DATABASE ASSESSMENT OFTHE EFFECTIVENESS OF BRAND VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITHTYPE 2 DIABETES MELLITUS

    Nov 1, 2007, 00:00

  • PGI17 INCREASED INPATIENT UTILIZATION FOLLOWING COLECTOMY IN ULCERATIVE COLITIS IN THE MEDICARE POPULATION

    Nov 1, 2007, 00:00

  • PEY5 COST-EFFECTIVENESS MODELING OF LUCENTIS VERSUS USUAL CARE IN AGE RELATED MACULAR DEGENERESCENCE

    Nov 1, 2007, 00:00

  • PCV44 COST-EFFECTIVENESS ANALYSIS OF THE USE OFVISIPAQUE COMPARED TO OMNIPAQUE IN THE UNITED KINGDOM (UK)

    Nov 1, 2007, 00:00

  • PCV21 COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN GREECE-THE ECON-APROS STUDY

    Nov 1, 2007, 00:00

  • PDB28 COST-EFFECTIVENESS ANALYSIS OF ACARBOSE IN THE PREVENTION OFTYPE 2 DIABETES IN SOUTH KOREA

    Nov 1, 2007, 00:00

  • CV4 BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION

    Nov 1, 2007, 00:00

  • PMC13 NONLINEAR SMOOTHING TO ASSESS PROBABILITIES OF ANTIBIOTIC-RESISTANT INFECTIONS IN THE COMUNITAT VALENCIANA (SPAIN)

    Nov 1, 2007, 00:00

  • PGI18 THE QUALITY INDICATORS OF NURSING CARE AMONG PATIENTS WITH ACUTE PANCREATITIS IN HUNGARY

    Nov 1, 2007, 00:00

  • PIN11 COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPES 2 AND 3 IN BRAZIL

    Nov 1, 2007, 00:00

  • PAA9 RISK-ADJUSTED COSTS AND OUTCOMES FOR MILD PERSISTENT ASTHMA PATIENTS ON ALTERNATIVE CONTROLLER THERAPIES

    Nov 1, 2007, 00:00

  • PCV37 COST-EFFECTIVENESS OF ATORVASTATIN, ROSUVASTATIN, AND SIMVASTATIN IN REDUCING LDL-CHOLESTEROL TO MEET THE EUROPEAN TARGET LEVEL—BAYESIAN META-ANALYSIS AND SIMULATION Peura P1. Martikainen JA1, Hallinen T1, Soini EJ1, Niskanen L2 Unive ...

    Nov 1, 2007, 00:00

  • PDB74 EFFECTS OF AN INTENSIFIED THERAPY WITH INSULIN GLARGINEAND INSULINE GLULISINE ON PATIENT REPORTED OUTCOMES IN DIABETES MELLITUS

    Nov 1, 2007, 00:00

  • CV2 COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FROM A CANADIAN HEALTH CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PHP33 RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS

    Nov 1, 2007, 00:00

  • PDB11 ASSOCIATION BETWEENTOPICAL CORTICOSTEROID USE AND DIABETES ONSET

    Nov 1, 2007, 00:00

  • PHP35 PROFILE OF PHYSICIANS' PRESCRIPTION IN GREECE

    Nov 1, 2007, 00:00

  • PAR20 ASSOCIATION BETWEEN DOSE CHANGES AND HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTSWHO RECEIVED INFLIXIMAB THERAPY

    Nov 1, 2007, 00:00

  • PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN

    Nov 1, 2007, 00:00

  • ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN

    Nov 1, 2007, 00:00

  • POS4 ECONOMIC IMPACT OF FRENCH NEW GUIDELINES ON POST-MENOPAUSAL OSTEOPOROSIS DIAGNOSIS

    Nov 1, 2007, 00:00

  • PIN29 AZITHROMYCIN PLUS CEFTRIAXONE VERSUS LEVOFLOXACIN IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN SPAIN. A COST-MINIMIZATION ANALYSIS

    Nov 1, 2007, 00:00

  • PGI21 THE VALUE OF INFORMATION OF SCREENING FOR HEREDITARY HEMOCHROMATOSIS

    Nov 1, 2007, 00:00

  • PCV26 COST-EFFECTIVENESS OF HIGH DOSE ATORVASTATIN COMPARED TO STANDARD DOSE PRAVASTATIN IN SECONDARY PREVENTION

    Nov 1, 2007, 00:00

  • PRS3 COSTS OF COPD IN SWEDEN ACCORDING TO DISEASE SEVERITY

    Nov 1, 2007, 00:00

  • PIH8 COST EFFECTIVENESS MODELLING OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS II, AN ULTRA-ORPHAN DISEASE

    Nov 1, 2007, 00:00

  • PND21 INSOMNIA AND SLEEP LOSS- WORKPLACE PRODUCTIVITY LOSS AND ASSOCIATED COSTS

    Nov 1, 2007, 00:00

  • REVIEWER ACKNOWLEDGMENT

    Nov 1, 2007, 00:00

  • PAA2 PREVALENCE OF UNCONTROLLED SEVERE PERSISTENT ASTHMA PATIENTS IN PNEUMOLOGY AND ALLERGY HOSPITAL UNITS IN SPAIN

    Nov 1, 2007, 00:00

  • PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)

    Nov 1, 2007, 00:00

  • PHP8 THE CHALLENGE OF A LEGITIMATE BUDGET IMPACT RATIONING CRITERION IN DRUG REIMBURSEMENT DECISIONS

    Nov 1, 2007, 00:00

  • Abstracts Index

    Nov 1, 2007, 00:00

  • PUK1 EFFECT OF LAUGHTER THERAPY ON STRESS AND HEALTH-RELATED QUALITY OF LIFE IN HEMODIALYSIS PATIENTS

    Nov 1, 2007, 00:00

  • PHP26 THE EFFECT OF INJURY SEVERITYANDTRAUMA CENTER DESIGNATION ON INPATIENT COSTS AND OUTCOMES IN HOSPITAL ADMISSIONS FORTRAUMATIC INJURY INTHE UNITED STATES

    Nov 1, 2007, 00:00

  • PCV11 ASSOCIATION AND CONTROL OF MAIN CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION SECTOR; A CROSS-SECTIONAL STUDY

    Nov 1, 2007, 00:00

  • PIN18 COST-EFFECTIVENESS ANALYSIS OF OSELTAMIVIR FOR INFLUENZA IN JAPAN- MODELING IN THE VIRUS EMERGING RESISTANT TO THE DRUG

    Nov 1, 2007, 00:00

  • PCV78 MONITORING AND ASSESSING ADHERENCE TO STATINS THERAPY IN REAL PRACTICE USING ADMINISTRATIVE DATABASES

    Nov 1, 2007, 00:00

  • PDB36 INSULIN USE AND COSTS OF CARDIOVASCULAR DISEASE EVENTS (CVD) AMONG PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PAR10 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF ANTI-TNF-A DRUGS IN PSORIATIC ARTHRITIS

    Nov 1, 2007, 00:00

  • PDB78 COMPARISONS BETWEEN ITEQAND DTSQ IN A SAMPLE OF TYPE 2 DIABETES MELLITUS PATIENTS

    Nov 1, 2007, 00:00

  • PMC14 ORDINAL OR CARDINAL? THE VAS STRIKES BACK

    Nov 1, 2007, 00:00

  • PIN14 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA SUSPECTED TO BE CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN SPAIN

    Nov 1, 2007, 00:00

  • PRS10 TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE

    Nov 1, 2007, 00:00

  • PR1 RECOMPUTING VALUES FOR EQ-5D IN ACCORDANCE WITH NICE APPRAISAL GUIDANCE

    Nov 1, 2007, 00:00

  • PCV43 DIRECT COSTS ASSOCIATED WITH THE POTENTIAL COMPLICATIONS OF INCREASED CARDIOMETABOLIC RISK STATES

    Nov 1, 2007, 00:00

  • PAR25 ASSOCIATION OF PERSISTENCE WITH ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPY AND HEALTH CARE COSTS IN PATIENTS WITH PSORIATIC ARTHRITIS

    Nov 1, 2007, 00:00

  • PCN22 COST-EFFECTIVENESS OF SUNITINIBAS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CANCER IN BELGIUM

    Nov 1, 2007, 00:00

  • PG126 VALIDATED MEASURES OF HEALTH RELATED QUALITY OF LIFE AND PRODUCTIVITY IN A POPULATION OF PATIENTS REPORTING CHRONIC CONSTIPATION

    Nov 1, 2007, 00:00

  • PMC33 GUIDELINES FOR ENSURING DEGREES OF VALIDITY IN HEALTH ECONOMIC MODELS

    Nov 1, 2007, 00:00

  • PSU2/ES4 THE RELATIVE COST-EFFECTIVENESS OF THE FENTANYL HCL PATIENT-ACTIVATED TRANSDERMAL SYSTEM (ITS) IN ACUTE POST-OPERATIVE PAIN MANAGEMENT (POPM) IN GREECE

    Nov 1, 2007, 00:00

  • PSK9 PRIOR AUTHORIZATION FOR TOPICAL PSORIASIS TREATMENTS- IS IT COST-BENEFICIAL FOR MANAGED CARE?

    Nov 1, 2007, 00:00

  • PHM21 UK COMMUNITY DERIVED UTILITIES USING TIME TRADE OFF FOR ORAL VERSUS SUBCUTANEOUS IRON CHELATION THERAPY FORTHETREATMENT OF CHRONIC IRON OVERLOAD

    Nov 1, 2007, 00:00

  • PCV39 COST UTILITY ANALYSIS OF CLOPIDOGREL IN ADDITION TO STANDARD CARE FOR ST-ELEVATED MYOCARDIAL INFARCTION-THE UK PERSPECTIVE

    Nov 1, 2007, 00:00

  • PUK23 ILLNESS REPRESENTATIONS IN RENAL TRANSPLANT RECIPIENTS

    Nov 1, 2007, 00:00

  • ED4 THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA

    Nov 1, 2007, 00:00

  • PMH41 A MULTI-CENTER STUDY OF ANTIPSYCHOTIC MEDICATION USE, TREATMENT DYNAMICS AND PATIENT SYMPTOMATOLOGY IN SPAIN. RESULTS FROM ANTIPSYCHOSISMONITOR INITIATIVE

    Nov 1, 2007, 00:00

  • CV7 COMPARISON OFTHE COST-EFFECTIVENESS OF SEROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN RELATION TO PATIENT CORONARY ARTERY DISEASE STATUS

    Nov 1, 2007, 00:00

  • PIN30 MULTI-CENTRE STUDY ON THE COSTS AND OUTCOMES OF ANTIBIOTIC TREATMENTS IN ITALY FOR COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI)

    Nov 1, 2007, 00:00

  • PCN18 SUNITINIB VS. INTERFERON-ALPHA (IFN-ALPHA) IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA (MRCC)- AN ECONOMIC EVALUATION

    Nov 1, 2007, 00:00

  • PMH3 EFFECTIVENESS OF OLANZAPINE TREATMENT FOR SCHIZOPHRENIA- 12-MONTH RESULTS OF THE POST MARKETING SURVEILLANCE IN JAPAN

    Nov 1, 2007, 00:00

  • PHP14 GENERIC PRESCRIPTION MEDICINES PRICE VARIATION AMONG COMMUNITY PHARMACIES, PUBLIC HOSPITAL PHARMACIES AND DISPENSING DOCTORS IN ZIMBABWE

    Nov 1, 2007, 00:00

  • PAR31 MULTILEVEL ANALYSIS- A NOVEL APPROACH FOR STATISTICAL ANALYSIS OF LONGITUDINAL STUDIES IN ORTHOPAEDICS

    Nov 1, 2007, 00:00

  • PHM2 BUDGET IMPACT (Bl) OF PARENTERAL IRON TREATMENT OF IRON DEFICIENCY ANAEMIA (IDA) IN SWITZERLAND

    Nov 1, 2007, 00:00

  • PMC18 THE ROLE OF CONCEPTUAL MODELS, ENDPOINT MODELS, AND CONCEPTUAL FRAMEWORKS WHEN MAKING TREATMENT BENEFIT CLAIMS TO THE FDA

    Nov 1, 2007, 00:00

  • PDB12 ROSIGLITAZONE IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES- IMPLEMENTATION OF BUDGET IMPACT ANALYSIS SOFTWARE

    Nov 1, 2007, 00:00

  • PCV75 THE ANALYSIS OF HEALTH AND ECONOMIC BENEFITS AS THE CONSEQUENCE OF THE REALIZATION CARDIOVASCULAR SYSTEM DISEASES PREVENTION PROGRAMME AMONG THE CHILDREN AND YOUTH OF SCHOOL AGE IN POLAND

    Nov 1, 2007, 00:00

  • PUK4 IN THE UNITED KINGDOM, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED FOR RENAL REPLACEMENT THERAPY (RRT)

    Nov 1, 2007, 00:00

  • PSK5 MANAGEMENT AND COST OF GENITAL WARTS IN ITALY

    Nov 1, 2007, 00:00

  • Prices for Innovative Pharmaceutical Products That Provide Health Gain- A Comparison Between Australia and the United States

    Nov 1, 2007, 00:00

  • PMH31 A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED KINGDOM (UK)

    Nov 1, 2007, 00:00

  • PMH2 A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN GERMANY

    Nov 1, 2007, 00:00

  • PCV28 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES AFTER HIP FRACTURE REPAIR (HFR)

    Nov 1, 2007, 00:00

  • PCN35 ASSESSING THE IMPACT ON STAFF RESOURCES AND PATIENT WAITING TIME OF A SWITCH FROM IVTO ORAL CHEMOTHERAPY WITH VINORELBINE

    Nov 1, 2007, 00:00

  • PDB29 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS ANDTHE COMBINED EFFECT OF HBA1C AND HYPOGLYCAEMIA REDUCTION

    Nov 1, 2007, 00:00

  • PND16 OBJECTIVE COSTS AND PREVALENCE OF COMORBIDITIES DURING THE YEAR FOLLOWING DIAGNOSIS FOR PERSONS WITH AND WITHOUT INSOMNIA

    Nov 1, 2007, 00:00

  • PIH20 ASSOCIATION BETWEEN METABOLIC SYNDROME AND QUALITY OF LIFE IN MALE STAINLESS STEEL WORKERS

    Nov 1, 2007, 00:00

  • PCV25 COST-EFFECTIVENESS OF PREHOSPITAL VERSUS INHOSPITAL THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2007, 00:00

  • PDB41 INSULIN AND INSULIN ANCILLARY USAGE, THE ANNUAL COST OF TREATING TYPE 2 DIABETES WITH INSULIN IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PND32 ALZHEIMER'S DISEASE PROGRESSION HEALTHY-YEAR EQUIVALENTS- STATED RISK-BENEFIT TRADE-OFF PREFERENCES

    Nov 1, 2007, 00:00

  • PG114 THE EPIDEMIOLOGY AND HEALTHMCARE RESOURCE USE IN PATIENTS WITH ULCERATIVE COLITIS-A POPULATION BASED UK STUDY

    Nov 1, 2007, 00:00

  • PAR19 COMPARISON OF ORAL LEFLUNOMIDE AND METOTREXATE SC FOR THE TREATMENT OF RHEUMATOID ARTHRITIS- AN APPROACH BASED ONTHE NUMBERTOTREAT

    Nov 1, 2007, 00:00

  • CV6 SIROLIMUS-ELUTING VERSUS BARE-METAL CORONARY STENTS- 18-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A CONTROLLED STUDY FOR THE REDUCTION OF CORONARY RESTENOSIS

    Nov 1, 2007, 00:00

  • PSM5 USE OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ)ANDTHE ENVIRONMENTAL TOBACCO SMOKE QUESTIONNAIRE (ETS-Q) IN AN INTERNATIONAL STUDY

    Nov 1, 2007, 00:00

  • PCN38 COST-ANALYSIS OF XELOXVS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING

    Nov 1, 2007, 00:00

  • PST2 A CRITICAL REVIEW OF PUBLISHED ECONOMIC MODELLING STUDIES IN ISCHAEMIC STROKE

    Nov 1, 2007, 00:00

  • SU1 COST-EFFECTIVENESS OF CYCLOOXYGENASE-2 INHIBITOR PARECOXIB COMPARED TO OPIOIDS AFTER NONCARDIAC SURGERY INTHE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PDB30 EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OFTYPE 2 DIABETES IN A SPANISH SETTING

    Nov 1, 2007, 00:00

  • PCN33 COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FORTHE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN BRAZIL

    Nov 1, 2007, 00:00

  • DB4 TREATMENT ADHERENCE AND BARRIERS TO ADHERENCE ARE ASSOCIATED WITH GLYCEMIC CONTROL AND EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE

    Nov 1, 2007, 00:00

  • PDB67 PERSISTENCE PATTERNS WITH ORAL ANTI-HYPERGLYCEMIC DRUG TREATMENT IN NEWLYTREATED PATIENTS— A POPULATION-BASED STUDY

    Nov 1, 2007, 00:00

  • PHP22 THE GREEK PHARMACEUTICAL EXPENDITURE DATA- EFFECTS OF THE NATIONAL ACCOUNTS' REVISION

    Nov 1, 2007, 00:00

  • PCN1 QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA

    Nov 1, 2007, 00:00

  • PPN5 LONGITUDINAL HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS)-A 12-WEEKS POST-HOC ANALYSIS OF THE PREGABALIN EFFECT UNDER ROUTINE MEDICAL PRACTICE

    Nov 1, 2007, 00:00

  • PHP40 PHARMACOECONOMIC EVALUATION IN THE IRISH HEALTH CARE SETTING

    Nov 1, 2007, 00:00

  • PG18 COST-EFFECTIVENESS OF ESOMEPRAZOLE IN THE TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX OESOPHAGITIS

    Nov 1, 2007, 00:00

  • PUK6 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH TACROLIMUS (PROGRAF®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION

    Nov 1, 2007, 00:00

  • PMC27 VALIDATION OF THE CAT-HEALTH SYSTEM-THE FIRST COMPUTER-ADAPTIVE TESTING SYSTEM IN SPAIN FOR EVALUATING THE HEALTH RELATED QUALITY OF LIFE OF ILL OR HEALTHY GENERAL POPULATION SUBJECTS

    Nov 1, 2007, 00:00

  • PIN19 A COST-EFFECTIVENESS ANALYSIS OF A PROPHYLACTIC CERVICAL CANCERVACCINE IN GERMANY- RESULTS FROM A HEALTH ECONOMIC MODEL

    Nov 1, 2007, 00:00

  • PAA20 PHARMACOECONOMIC ANALYSIS OF A NEW CONCEPT FOR SYMBICORT USE IN BRONCHIAL ASTHMA PATIENTS

    Nov 1, 2007, 00:00

  • PCN28 ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2-3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER- A FINNISH PERSPECTIVE

    Nov 1, 2007, 00:00

  • PCV86 THE IMPACT OF LOWERING SYSTOLIC BLOOD PRESSURE ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS IN GREECE-THE ECON-APROS STUDY

    Nov 1, 2007, 00:00

  • PMH60 A PHARMACOECONOMIC COMPARISON OF ESCITALOPRAM AND DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PDB43 COMPARATIVE STUDY OF ANNUAL TREATMENT COSTS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN

    Nov 1, 2007, 00:00

  • PMH19 COMORBIDITYAND COSTS IN GENERALIZED ANXIETY DISORDERS AND FIBROMYALGIA SYNDROME IN THE PRIMARY CARE SETTING (PCS)- A COMPARISON OF TWO DISORDERS WITH HIGH DEMAND OF CARE

    Nov 1, 2007, 00:00

  • PCV7 DIFFERENCES IN CHOLESTEROL LEVELS BETWEEN STATIN AND FIBRATE TREATED PATIENTS IN FRENCH, ITALIAN AND UNITED KINGDOM PRIMARY CARE

    Nov 1, 2007, 00:00

  • PCN69 PATIENT-REPORTED IMPAIRMENT OF EUROQOL HEALTH STATES AND PREFERENCE-WEIGHTED UTILITY IN ADVANCED RENAL CELL CARCINOMA IN A RECENT CLINICAL TRIAL

    Nov 1, 2007, 00:00

  • PMH57 EFFECTIVENESS OF A PSYCHOSOCIAL INTERVENTION PROGRAM FOR CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE IN THE PREVENTION OR REDUCTION CAREGIVER BURDEN EDUCA STUDY

    Nov 1, 2007, 00:00

  • PHP36 PATIENT TRANSFER DECREASE AND HEALTH INSURANCE COSTS SAVINGS ASSOCIATED WITH TELEMEDICINE CONSULTATION. EXAMPLE OF THE TELEMEDICINE NETWORK OF “MIDI-PYRéNéES” (RTR)

    Nov 1, 2007, 00:00

  • PHP10 COMPLEMENT OR SUBSTITUTE? COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND PRESCRIPTION DRUG USE AMONG AFRICAN AMERICANS

    Nov 1, 2007, 00:00

  • PDB19 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH SITAGLIPTIN- AN ECONOMIC EVALUATION USING A VALIDATED ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA

    Nov 1, 2007, 00:00

  • PR2 NON-PERSISTENT USE OF ORAL ANTIDIABETIC DRUGS LEADS TO 20% DECREASED CHANCE OF HBA1C GOAL-ATTAINMENT IN DAILY CLINICAL PRACTICE

    Nov 1, 2007, 00:00

  • PHP30 HEALTH OUTCOMES AMONG INDIVIDUALS WITH AND WITHOUT HEALTH INSURANCE IN THE UNITED KINGDOM- RESULTS OF A MATCHED SAMPLE ANALYSIS OF A RETROSPECTIVE DATABASE

    Nov 1, 2007, 00:00

  • PCN70 UTILITYVALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKAEMIA (CML)- ESTIMATES FROM LAYPERSONS IN AUSTRALIA, THE UNITED KINGDOM (UK) AND CANADA

    Nov 1, 2007, 00:00

  • ES5 DOES ARTHROSCOPIC ACROMIOPLASTY PROVIDE ANY ADDITIONAL VALUE IN THE TREATMENT OF SHOULDER IMPINGEMENT SYNDROME? ATWO-YEAR RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2007, 00:00

  • PCN57 BASIC ATTITUDE TO USE OF GENERIC ANTI-CANCER DRUGS FOR BREAST CANCER TREATMENT IN JAPAN

    Nov 1, 2007, 00:00

  • International Price Comparisons for Novel and Follow-on Drugs- A Response

    Nov 1, 2007, 00:00

  • PHP28 DEVELOPMENT OF THE CAT-HEALTH SYSTEM-THE FIRST COMPUTER-ADAPTIVE TESTING SYSTEM IN SPAIN FOR EVALUATING THE HEALTH RELATED QUALITY OF LIFE OF ILL OR HEALTHY GENERAL POPULATION SUBJECTS

    Nov 1, 2007, 00:00

  • PMH10 REDUCTION IN SUICIDAL IDEATION, VIOLENT BEHAVIOUR, AND SELF INJURY AFTER TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- 12 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA

    Nov 1, 2007, 00:00

  • PND29 RETROSPECTIVE MEASUREMENT OF UNCODED DISEASE OUTCOMES IN A CLAIMS DATABASE

    Nov 1, 2007, 00:00

  • PHP12 RETROSPECTIVE DRUG UTILIZATION REVIEW- IMPACT OF PHARMACIST INTERVENTIONS ON PHYSICIAN PRESCRIBING

    Nov 1, 2007, 00:00

  • PIN2 THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS OF INFLUENZA VACCINATION REIMBURSEMENT IN CHILDREN WITH MALIGNANCIES IN POLAND

    Nov 1, 2007, 00:00

  • PDB72 EMPIRIC PSYCHOLOGICAL TYPING OF PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED ORALLY, AND CORRESPONDING GLYCAEMIC CONTROL/RESULTS FROM THE SETT2D SURVEY

    Nov 1, 2007, 00:00

  • POS10 COST-OF-ILLNESS STUDY OF HIP FRACTURE AMONG KOREAN ELDERLY WOMEN- INCIDENCE-BASED APPROACH

    Nov 1, 2007, 00:00

  • PCV59 ASSESSMENT OF THE USE OF ANGIOTENSIN RECEPTOR BLOCKERS IN THE EUROPEAN UNION PEDIATRIC POPULATION FOR TREATING ESSENTIAL HYPERTENSION

    Nov 1, 2007, 00:00

  • PMH47 DEVELOPING COST-EFFECTIVE FORMULARIES- IMPLICATIONS FOR NEW ATYPICAL ANTIPSYCHOTICS

    Nov 1, 2007, 00:00

  • PIN42 EVALUATING THE CLINICAL EFFECTS AND THE COST-EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION WITHIN AN ORGANISED POPULATION-BASED SCREENING SETTING—CASE FINLAND

    Nov 1, 2007, 00:00

  • Meeting on the FDA Draft Guidance on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PIN22 A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF DIRECT AND INDIRECT IMMUNITY CONFERRED BY THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7)

    Nov 1, 2007, 00:00

  • PDB47 LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH INSULIN ASPART VERSUS HUMAN BOLUS INSULIN IN TYPE 2 DIABETES PATIENTS IN THE SWEDISH SETTING

    Nov 1, 2007, 00:00

  • PCV53 STATIN USE AMONG PATIENTS WITH CONFIRMED CORONARY ARTERY DISEASE (CAD) OR RELATED RISK FACTORS-A COMPARISON BETWEEN EUROPE THE UNITED STATES (US)

    Nov 1, 2007, 00:00

  • PAA11 ECONOMIC EVALUATION OF SECOND-LINE THERAPIES IN ADULT PATIENTS WITH ASTHMA WHEN CONSIDERING COMPLIANCE—AN ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PCV94 EFFECTS OF COMORBID CONDITIONS AMONG THE OVERWEIGHT/OBESE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT

    Nov 1, 2007, 00:00

  • PCN19 A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W DA) COMPARED TO WEEKLY EPOETIN ALFA (QW EA) OR EPOETIN BETA (QW EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)-THE GERMAN CASE

    Nov 1, 2007, 00:00

  • PCN71 CONJOINT ANALYSIS ATECHNIQUE TO DEVELOP A QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH LUNG CANCER

    Nov 1, 2007, 00:00

  • PDB13 THE COST OFTHE INEFFICIENCY IN DIABETES IN HEALTH PRIMARY CARE

    Nov 1, 2007, 00:00

  • PCV71 AN EVALUATION OF STATIN PERFORMANCES BIVARIATE AND TRIVARIATE SELECTION RULE APPROACH

    Nov 1, 2007, 00:00

  • PCV13 RISK OF MAJOR BLEEDING DURING CONCOMITANT USE OF ANTIBIOTIC DRUGS AND COUMARIN ANTICOAGULANTS

    Nov 1, 2007, 00:00

  • PDB16 GLYCEMIC CONTROL WITH INSULIN GLARGINE PLUS GLULISINE VERSUS PREMIX IN REALWORLD PRACTICES—A RANDOMIZED, PROSPECTIVE, OBSERVATIONAL STUDY

    Nov 1, 2007, 00:00

  • POS11 FALL-RELATED HOSPITALIZATION AND FACILITY COSTS AMONG RESIDENTS RECEIVING LONG-TERM CARE

    Nov 1, 2007, 00:00

  • PRS15 EQ-5D UTILITIES ASSOCIATED WITH LEVELS OF COPD SEVERITY-A META-ANALYTIC APPROACH

    Nov 1, 2007, 00:00

  • PCV88 QUALITY OF LIFE AS A PREDICTOR OF TREATMENT COMPLIANCE DURING ROUTINE HYPERTENSION MANAGEMENT- RESULTS OF PROSPECTIVE EVALUATION

    Nov 1, 2007, 00:00

  • RS1 A RETROSPECTIVE, OBSERVATIONAL STUDY COMPARING OUTCOMES OF ASTHMATREATMENT WITH FIXED COMBINATIONS OF INHALED CORTICOSTEROID AND LONG-ACTING â2-AGONIST (ICS/LABA) IN REAL-LIFE PRACTICE

    Nov 1, 2007, 00:00

  • PCV14 CHARACTERIZATION, RISK FACTORS, CLINICAL OUTCOMES, AND ECONOMIC CONSEQUENCES OF BLEEDING ASSOCIATED WITH CARDIAC SURGERY- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2007, 00:00

  • PMH9 TREATMENT RETENTION WITH RISPERIDONE LONG ACTING INJECTION (RLAI) IN EUROPEAN PATIENTS WITH SCHIZOPHRENIA- 12-MONTH INTERIM RESULTS FROM ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)

    Nov 1, 2007, 00:00

  • PSK4 COST COMPARISON BETWEEN TWO ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPIES IN PATIENTS WITH PSORIASIS USING AVERAGE SALES PRICE

    Nov 1, 2007, 00:00

  • PIH22 WILLINGNESS TO PAY OF YOUNG GREEK WOMEN FORTHE NEW ANTI-HUMAN PAPILOMA VIRUS VACCINE

    Nov 1, 2007, 00:00

  • Development and Validation of the Congestion Quantifier Seven-Item Test (CQ7)- A Screening Tool for Nasal Congestion

    Nov 1, 2007, 00:00

  • RS4 ASTHMA COSTS AND UTILIZATION IN A MANAGED CARE ORGANIZATION

    Nov 1, 2007, 00:00

  • MC1 ASSESSING THE GENERALISABILITY OF COST EVALUATION RESULTS USING THE EUCLIDEAN METRIC AND PRINCIPAL COMPONENTS ANALYSIS- LESSON FROM A HIGH-COST INNOVATION IN ONCOLOGY

    Nov 1, 2007, 00:00

  • PEY15 HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS IN FRANCE

    Nov 1, 2007, 00:00

  • PHM4 CLINICO-ECONOMICAL ANALYSIS OF FERRUM LEKVS FENULS IN IRON-DEFICIENT ANEMIA IN ELDERLY PATIENTS

    Nov 1, 2007, 00:00

  • PEY6 COST OF CATARACT SURGERY AFTER IMPLANTATION OF THREE INTRAOCULAR LENSES WITH SQUARE EDGES

    Nov 1, 2007, 00:00

  • PND14 COST-EFFECTIVENESS OF PREGABALIN ADD-ON MEDICATION IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY IN FINLAND

    Nov 1, 2007, 00:00

  • EC2 AN ECONOMIC EVALUATION OF DASATINIB AS A TREATMENT FOR CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA IN SCOTLAND

    Nov 1, 2007, 00:00

  • PUK2 COMPARING THE CLINICAL OUTCOMES FOLLOWING URINARY INCONTINENCE TREATMENT BY DIFFERENT TYPE OF SURGERY

    Nov 1, 2007, 00:00

  • PSU1 COST-EFFECTIVENESS OF STAPLED HAEMORRHOIDOPEXY (PPH) COMPARED WITH MILLIGAN-MORGAN TECHNIQUE MM IN PATIENTS IN WHOM SURGICAL INTERVENTION IS CONSIDERED APPROPRIATE FORTHETREATMENT OF PROLAPSED INTERNAL HAEMORRHOIDS IN UNITED KINGDOM

    Nov 1, 2007, 00:00

  • Real World Data

    Sep 1, 2007, 00:00

  • Quality of Life Assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of Patients on Renal Replacement Therapy- A Systematic Review and Meta-Analysis

    Sep 1, 2007, 00:00

  • Comparison of Persistence Rates with Angiotensin-Converting Enzyme Inhibitors Used in Secondary and Primary Prevention of Cardiovascular Disease

    Sep 1, 2007, 00:00

  • Economic Evaluation of a Bayesian Model to Predict Late-Phase Success of New Chemical Entities

    Sep 1, 2007, 00:00

  • Time from Sexually Transmitted Infection Acquisition to Pelvic Inflammatory Disease Development- Influence on the Cost-Effectiveness of Different Screening Intervals

    Sep 1, 2007, 00:00

  • The Distribution of the Cost of Multiple Sclerosis in the UK- How Do Costs Vary by Illness Severity?

    Sep 1, 2007, 00:00

  • Evidence for Coverage Decisions- The Need for a Reality Check

    Sep 1, 2007, 00:00

  • Item-Based versus Subscale-Based Mappings from the SF-36 to a Preference-Based Quality of Life Measure

    Sep 1, 2007, 00:00

  • Budget Impact Analyses Get Some Respect

    Sep 1, 2007, 00:00

  • Principles of Good Practice for Budget Impact Analysis- Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis

    Sep 1, 2007, 00:00

  • Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients

    Sep 1, 2007, 00:00

  • Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer

    Sep 1, 2007, 00:00

  • The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks

    Sep 1, 2007, 00:00

  • Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey

    Sep 1, 2007, 00:00

  • Using Real-World Data for Coverage and Payment Decisions- The ISPOR Real-World Data Task Force Report

    Sep 1, 2007, 00:00

  • Regarding Probabilistic Analysis and Computationally Expensive Models- Necessary and Required?

    Jul 1, 2007, 00:00

  • The Methodological Quality of Economic Evaluations of Guideline Implementation into Clinical Practice- A Systematic Review of Empiric Studies

    Jul 1, 2007, 00:00

  • Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome- An Analysis of the TENOR Study

    Jul 1, 2007, 00:00

  • Literature Review of Questionnaires Assessing Vertigo and Dizziness, and Their Impact on Patients' Quality of Life

    Jul 1, 2007, 00:00

  • Validation of a Condition-Specific Measure for Women Having an Abnormal Screening Mammography

    Jul 1, 2007, 00:00

  • Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney Cancer

    Jul 1, 2007, 00:00

  • Estimation of Patient Preference-Based Utility Weights from the Functional Assessment of Cancer Therapy—General

    Jul 1, 2007, 00:00

  • The Cost-Effectiveness of Stem Cell Transplantations from Unrelated Donors in Adult Patients with Acute Leukemia

    Jul 1, 2007, 00:00

  • Diabetes Cost Model of a Hospital in Thailand

    Jul 1, 2007, 00:00

  • Assessing Differences in Utility Scores- A Comparison of Four Widely Used Preference-Based Instruments

    Jul 1, 2007, 00:00

  • Decision Models Need to be “Fit for Purpose” for Decision-Making- Response to Caro et al.

    Jul 1, 2007, 00:00

  • The Impact of Gout on Work Absence and Productivity

    Jul 1, 2007, 00:00

  • PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • MC3 CONTROLLING FOR COMORBIDITIES USING VARIATIONS OF THE CHARLSON COMORBIDITY INDEX ON MEDICARE CLAIMS DATA-THE CASE OF OVERACTIVE BLADDER

    May 1, 2007, 00:00

  • CASE 3 APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN

    May 1, 2007, 00:00

  • PPN19 VALIDATION OF INGUINAL PAIN QUESTIONNAIRE

    May 1, 2007, 00:00

  • PSK5 QUALITY OF DERMATOLOGIC CARE DELIVERED BY PHYSICIAN ASSISTANTS-AN ANALYSIS OF CLOTRIMAZOLE/BETAMETHASONE PROPIONATE PRESCRIPTIONS

    May 1, 2007, 00:00

  • PAR3 COST-EFFECTIVENESS OF LUMIRACOXIB COMPARED TO CELECOXIB FOR THE TREATMENT OF OSTEOARTHRITIS IN CANADA

    May 1, 2007, 00:00

  • PPN14 OFF-LABEL OPIOID USE IN THE TREATMENT OF CHRONIC PAIN

    May 1, 2007, 00:00

  • PAA23 UNDERSTANDING PATIENT PERCEPTION OF THERAPY- DEVELOPMENT OF A WEEKLY DIARY TO DETERMINE WHETHER PATIENTS WITH ASTHMA CAN FEEL THEIR MAINTENANCE INHALER WORKING RIGHT AWAY

    May 1, 2007, 00:00

  • PND15 ECONOMIC CONSEQUENCES OF GENERIC SUBSTITUTION FOR ANTIEPILEPTIC MEDICATION-THE CASE OF LAMOTRIGINE

    May 1, 2007, 00:00

  • PND5 DOES SPECIALTY CARE OF SPINA BIFIDA PATIENTS INFLUENCE COST OF CARE?

    May 1, 2007, 00:00

  • PCV17 COMPARING THE COST OF MICROSURGERY AND RADIOSURGERY FOR THE MANAGEMENT OF VESTIBULAR SCHWANNOMA

    May 1, 2007, 00:00

  • PIN38 ASSESSING THE ASSOCIATION BETWEEN COMPLIANCE AND THERAPEUTIC FAILURE FOR ANTIRETROVIRAL DRUGS IN HIV POSITIVE PATIENTS

    May 1, 2007, 00:00

  • PMH32 HEALTH SERVICE AND PRESCRIPTION DRUG USE AND COSTS AMONG HISPANIC AND NON-HISPANIC CAUCASIAN SUBJECTS WITH ADHD

    May 1, 2007, 00:00

  • PQ1 HOSPITAL COMPLIANCE WITH ACCP GUIDELINES FOR ANTICOAGULANT THERAPY AND JCAHO PERFORMANCE MEASURES

    May 1, 2007, 00:00

  • PCV12 SEASONAL VARIATIONS OF THE OCCURRENCE OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY BETWEEN 2000-2004

    May 1, 2007, 00:00

  • PCN43 ADHERENCE TO GUIDELINES FOR USE OF ERYTHROPOIESIS STIMULATING PROTEINS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA-TRENDS FROM ELECTRONIC MEDICAL RECORDS

    May 1, 2007, 00:00

  • PHP21 DETERMINANTS OF STATE MEDICAID PER CAPITA PRESCRIPTION DRUG EXPENDITURES-A STRUCTURE EQUATION MODELING APPROACH

    May 1, 2007, 00:00

  • PMH20 THE ECONOMIC COSTS TO MANAGED CARE ORGANIZATIONS OF EXCESS MD WITHDRAWAL FROM DULOXETINE TREATMENT- AN OPPORTUNITY COSTS MODEL

    May 1, 2007, 00:00

  • RS1 COST EFFECTIVENESS OF QUANTIFERON IN SCREENING FOR TUBERCULOSIS INFECTION IN CLOSE CONTACTS IN JAPAN

    May 1, 2007, 00:00

  • PAA19 THE EVOLUTION OF ASTHMA GUIDELINES FOR CHILDREN

    May 1, 2007, 00:00

  • PMC7 A PRE-POST TIME IN MOTION METHODOLOGY TO EXAMINE PRODUCT WASTAGE REDUCTION- PILOT RESULTS IN MAGNETIC RESONANCE CONTRAST MEDIA PHARMACY BULK PACK

    May 1, 2007, 00:00

  • PHM3 ANEMIA IN LONG-TERM CARE PATIENTS- PREVALENCE AND RELATIONSHIP TO FALLS

    May 1, 2007, 00:00

  • PCN4 BUDGET IMPACT ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

    May 1, 2007, 00:00

  • PCN52 COMPARISON OF IMPACT OF ELEVEN TYPES OF ADVANCED CANCER ON QUALITY OF LIFE

    May 1, 2007, 00:00

  • MC2 COMPARISON OF TRADITIONAL MULTIVARIABLE LOGISTIC REGRESSION AND PROPENSITY SCORE APPROACHES FOR CONTROLLING FOR TREATMENT SELECTION BIAS USING MONTE CARLO SIMULATION

    May 1, 2007, 00:00

  • AR1 COST-EFFECTIVENESS OF ETANERCEPT AND INFLIXIMAB IN THE REAL-WORLD SETTING—AN ESTIMATE BASED ON PUBLISHED GERMAN DATA ON RESPONSE AND ADHERENCE

    May 1, 2007, 00:00

  • PHP11 THE VOLUNTARY INCENTIVE STRUCTURE OF PEDIATRIC EXCLUSIVITY AND ITS IMPACTS ON PHARMACEUTICAL INDUSTRY BEHAVIOR AND GENERIC DRUG ENTRIES

    May 1, 2007, 00:00

  • PCN16 THE RELATIONSHIP BETWEEN SHORT-TERM RESPONSE AND LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA

    May 1, 2007, 00:00

  • PND20 UNDERSTANDING LIMITATIONS OF PATIENT REPORTED CLINICAL OUTCOMES IN LUPUS

    May 1, 2007, 00:00

  • PIN14 A CANADIAN COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR FOR HIV INFECTION IN TREATMENTEXPERIENCED ADULTS

    May 1, 2007, 00:00

  • PDB19 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS

    May 1, 2007, 00:00

  • PGI7 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CONSTIPATION (C-ONLY) AND CO-OCCURRING IRRITABLE BOWEL SYNDROME AND CONSTIPATION (IBS+C) COMPARED TO MIGRAINE IN A LARGE MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PAR5 COST-EFFECTIVENESS OF EXTENDED-RELEASE AND IMMEDIATE-RELEASE TRAMADOL FOR THE TREATMENT OF CHRONIC OSTEOARTHRITIS PAIN

    May 1, 2007, 00:00

  • PR4 VALUING CHILDREN'S HEALTH FOR ECONOMIC EVALUATIONS-THEORETICAL AND METHODOLOGICAL CONSIDERATIONS

    May 1, 2007, 00:00

  • PAR9 IMPACT OF PATIENT'S OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • PCN44 INTEGRATION OF QUALITY OF LIFE WITH SURVIVAL FOR COMPARATIVE HEALTH OUTCOME ASSESSMENT

    May 1, 2007, 00:00

  • NE4 COST-UTILITY ANALYSIS EVALUATING LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN FOR POSTHERPETIC NEURALGIA IN SCOTLAND

    May 1, 2007, 00:00

  • OB3 CORRELATION OF WEIGHT TO CARDIOMETABOLIC RISK AS IDENTIFIED BY ICD-9 DIAGNOSIS CODES AND PRESCRIPTIONS IN PRIMARY CARE

    May 1, 2007, 00:00

  • PIH2 E-PRESCRIBING REDUCES BEERS PRESCRIBING AMONG THE ELDERLY

    May 1, 2007, 00:00

  • PDB30 HEALTH RELATED QUALITY OF LIFE ON BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES IN THE GENERAL ADULT POPULATION IN ENGLAND

    May 1, 2007, 00:00

  • PPN18 SYSTEMATIC OVERVIEW OF THE PSYCHOMETRIC PROPERTIES OF THE BRIEF PAIN INVENTORY IN MALIGNANT AND NON-MALIGNANT PAIN

    May 1, 2007, 00:00

  • PCN32 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

    May 1, 2007, 00:00

  • PDB4 THE EFFECTIVENESS OF DANCE THERAPY AMONG ADULT PATIENTS WITH DIABETES MELLITUS TYPE II

    May 1, 2007, 00:00

  • PHP17 PREVALENCE OF CLINICALLY IMPORTANT POTENTIAL DRUG-DRUG INTERACTIONS IN REGIONE EMILIA ROMAGNA, ITALY

    May 1, 2007, 00:00

  • PIN20 PHARMACOECONOMIC ANALYSIS OF SEVERE COMMUNITYACQUIRED PNEUMONIA TREATMENT

    May 1, 2007, 00:00

  • PMC2 THE EFFECT OF PHARMACIST CONSULTATION ON PATIENT MEDICATION ADHERENCE-AN INSTRUMENTAL VARIABLE APPROACH

    May 1, 2007, 00:00

  • PDB21 PRICE AND UTILIZATION OF ORAL ANTI-DIABETIC MEDICATIONS FROM 1991 TO 2005 IN U.S. MEDICAID PROGRAMS

    May 1, 2007, 00:00

  • PCN8 COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN FOR THE TREATMENT OF POST MENOPAUSAL HORMONE-RECEPTOR POSITIVE BREAST CANCER (BC) IN THE ADJUVANT SETTING IN BRAZIL

    May 1, 2007, 00:00

  • PIN16 COST-EFFECTIVENESS ANALYSIS OF IMMUNIZATION STRATEGIES FOR THE CONTROL OF MENINGOCOCCAL INFECTIOUS DISEASE

    May 1, 2007, 00:00

  • PCV69 BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTICENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. ...

    May 1, 2007, 00:00

  • DB4 RETESTING OF HEMOGLOBIN A1C AFTER OUT-OF-RANGE RESULTS- CLINICAL PRACTICE VERSUS GUIDELINES

    May 1, 2007, 00:00

  • PMC5 EVALUATING AN ONLINE CALCULATOR FOR ANALYZING INCREMENTAL NET BENEFIT AND THE EXPECTED VALUE OF PERFECT INFORMATION FROM PATIENT LEVEL DATA

    May 1, 2007, 00:00

  • PCN35 OUTPATIENT USE OF HEMATOPOIETIC COLONY STIMULATING FACTORS (CSF) AMONG ELDERLY CANCER PATIENTS WITH CHEMOTHERAPY

    May 1, 2007, 00:00

  • PND22 IMPLICATIONS OF COMORBIDITY ON COSTS FOR PATIENTS WITH ALZHEIMER'S DISEASE

    May 1, 2007, 00:00

  • PND21 PRODUCT ENHANCEMENTS DECREASE THE INCIDENCE OF INJECTION SITE REACTIONS AND PAIN RESULTING IN IMPROVED ADHERENCE TO THERAPY IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2007, 00:00

  • PIN2 RETROSPECTIVE COMPARISON OF TREATMENT OUTCOMES AMONG HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON 2A OR 2B PLUS RIBAVIRIN AT DIFFERENT VA MEDICAL CENTERS

    May 1, 2007, 00:00

  • PDB29 RELATIONSHIP BETWEEN EATING HEALTHY FOODS AND REGULAR EXERCISE AND PHYSICAL HEALTH, MENTAL HEALTH, AND HEALTH STATUS IN TYPE II DIABETICS

    May 1, 2007, 00:00

  • PCV58 HOSPITAL POLICIES FOR TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE

    May 1, 2007, 00:00

  • PAA1 RELATIONSHIP BETWEEN MEASURES OF ASTHMA CONTROL AND COMBINATION THERAPY TREATMENT REGIMENS IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA

    May 1, 2007, 00:00

  • PMH40 12-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI)- INTERIM RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY PROJECT CONDUCTED IN SPAIN, ...

    May 1, 2007, 00:00

  • PR1 ABILITY OF SF-36 AND EQ-5D TO DISCRIMINATE AMONG DISEASE ACTIVITY LEVELS IN LUPUS

    May 1, 2007, 00:00

  • PMH44 THE PREDICTIVE VALIDITY OF DIFFERENT ADHERENCE MEASURES USING ADMINISTRATIVE CLAIMS DATA

    May 1, 2007, 00:00

  • PHP14 POLYPHARMACY IN ELDERLY PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY- SATISFACTION AND COSTS

    May 1, 2007, 00:00

  • PIN24 THE ECONOMIC IMPACT OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS AUREUS BACTEREMIA IN KOREA

    May 1, 2007, 00:00

  • PCASE2 EVALUATION OF LEVALBUTEROL USE IN A >600 BED TEACHING HOSPITAL

    May 1, 2007, 00:00

  • PCN49 LINGUISTIC VALIDATION OF THE FACT-HEAD AND NECK IN 8 LANGUAGES FOR INDIA

    May 1, 2007, 00:00

  • PMC31 PROPOSAL FOR A METHODOLOGICAL CHANGE OF PRACTISE- SEPARATING THE PROCESS OF ESTIMATING CLINICAL EFFECTIVENESS FROM ECONOMIC EVALUATIONS

    May 1, 2007, 00:00

  • PCV46 EFFECT OF MENTAL DISORDERS ON HEALTH CARE COST AMONG ELDERLY WITH DISEASES OF THE HEART

    May 1, 2007, 00:00

  • PAA11 A 4-YEAR ASSESSMENT OF SUB-ACUTE LACK OF ASTHMA CONTROL IN A REAL-WORLD SETTING

    May 1, 2007, 00:00

  • IN1 COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR/R FOR HIV INFECTION IN TREATMENT-EXPERIENCED ADULTS IN THE US- UNDERSTANDING THE UNCERTAINTY IN THE ESTIMATES

    May 1, 2007, 00:00

  • PMC32 SYSTEMATIC BIAS BETWEEN INTERNET AND MAIL SURVEYS- IMPLICATION FOR SCALING OF CONJOINT QUESTIONS

    May 1, 2007, 00:00

  • PAA13 CATEGORIES AND TRANSITION PATTERNS OF GUIDELINE INFORMED CONTROL IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA

    May 1, 2007, 00:00

  • PAA4 ADVERSE DRUG REACTIONS IN ECONOMIC EVALUATIONS

    May 1, 2007, 00:00

  • PHP46 THE RELATIVE PERFORMANCE OF PHARMACEUTICAL SECTOR SECURITY PRICES DURING STOCK MARKET CRASHES

    May 1, 2007, 00:00

  • PIH7 CHARACTERISTICS ASSOCIATED WITH BENZODIAZEPINE USAGE IN ELDERLY OUTPATIENTS IN TAIWAN

    May 1, 2007, 00:00

  • PDB28 IMPACT OF INITIATING OR CONVERTING TO TREATMENT WITH AN INSULIN ASPART ANALOG PEN ON MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS ON VIAL/SYRINGE INSULIN

    May 1, 2007, 00:00

  • CASE 6 INCORPORATION OF COST EFFECTIVENESS FOR FORMULARY ADDITIONS AT A CANCER CENTER

    May 1, 2007, 00:00

  • PMH45 SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF UTILITY SCORES IN ALZHEIMERS DISEASE

    May 1, 2007, 00:00

  • PND25 A REVIEW OF HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN CHILDREN AND ADOLESCENTS WITH EPILEPSY

    May 1, 2007, 00:00

  • PEY4 INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR ACUTE OTITIS MEDIA

    May 1, 2007, 00:00

  • PCN11 IS EARLY REPLACEMENT OF HORMONE THERAPY (HT) BY SEQUENTIAL CHEMOTHERAPY (CT) COST-EFFECTIVE IN HORMONE-RECEPTOR (HR) POSITIVE ADVANCED BREAST CANCER (ABC)?

    May 1, 2007, 00:00

  • PCV42 USE OF RECOMMENDED MEDICATIONS AFTER MYOCARDIAL INFARCTION IN AUSTRIA

    May 1, 2007, 00:00

  • PGI17 SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE, CONCOMITANT DISEASES, HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY-A DATABASE STUDY IN A US COHORT

    May 1, 2007, 00:00

  • PMC16 A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION IN FRANCE, GERMANY AND UK

    May 1, 2007, 00:00

  • PCV45 ARE MINORITIES MORE LIKELY TO BE INITIALLY DIAGNOSED OF HYPERTENSION DURING NON-OFFICE-BASED VISITS? EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY 1996-2003

    May 1, 2007, 00:00

  • MC1 METHODS OF MODEL CALIBRATION-A COMPARATIVE APPROACH

    May 1, 2007, 00:00

  • PMC15 A RETROSPECTIVE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND OTHER EFFICACY ENDPOINTS IN TOP BRAND NAME PRODUCT LABELS IN UNITED STATES

    May 1, 2007, 00:00

  • PDB13 COPAYMENT LEVEL AND MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS MANAGED WITH INSULIN ASPART PEN THERAPY

    May 1, 2007, 00:00

  • PUK15 DRUG UTILIZATION AND COSTS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2007, 00:00

  • PIH8 MEDICARE PART D AND STATE-LEVEL VARIATIONS IN MEDICARE ADVANTAGE PARTICIPATION

    May 1, 2007, 00:00

  • PCV52 THE IMPACT OF SIMVASTATIN LAUNCHING ON EXISTING LIPITOR PATIENTS IN A MANAGED CARE SETTING

    May 1, 2007, 00:00

  • PUK18 LINGUISTIC VALIDATION OF THE NOCTURIA QUALITY OF LIFE (N-QOL) QUESTIONNAIRE IN 10 LANGUAGES

    May 1, 2007, 00:00

  • PDB2 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS

    May 1, 2007, 00:00

  • PAR19 ARTHRITIS AND HEALTH-RELATED QUALITY OF LIFE AMONG ADULTS IN OHIO

    May 1, 2007, 00:00

  • CV1 IMPACT OF A TARGETED PATIENT COMMUNICATION ENCOURAGING GREATER GENERIC STATIN USE

    May 1, 2007, 00:00

  • PCN48 STANDARD GAMBLE TECHNIQUES FOR THE MEASUREMENT OF TREATMENT RELATED TOXICITY IN ONCOLOGY- APPLICATION TO ADVANCED STAGE PROSTATE CANCER

    May 1, 2007, 00:00

  • PHP39 QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN KOREA

    May 1, 2007, 00:00

  • CS1 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS AND DRUG COSTS IN ELDERLY PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS

    May 1, 2007, 00:00

  • PGI10 INCORPORATING NON-ADHERENCE RESULTING FROM MULTIPLE DAILY DOSE REGIMENS INTO ECONOMIC MODELS- COST-UTILITY ANALYSIS OF ALTERNATIVE GASTROINTESTINAL PROPHYLAXIS STRATEGIES IN PREVENTING NSAID ASSOCIATED GASTROINTESTINAL COMPLICATIONS I ...

    May 1, 2007, 00:00

  • PMC29 ICER VS. IERC-THEORETICAL HEALTH ECONOMICS VS. PRACTICAL DECISION MAKER BASED VALUE EVIDENCE

    May 1, 2007, 00:00

  • PND17 PREVALENCE OF NON-ADHERENCE TO PARKINSON'S DISEASE MEDICATIONS AND ITS IMPACT ON SYMPTOM PROGRESSION IN A MEDICARE POPULATION

    May 1, 2007, 00:00
  • «
  • 161 (current)
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • »